Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha), as a first- line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Final results from the run-in phase of a placebo-controlled randomized phase II

被引：10

作者：

Duhoux, Francois P.

Jager, Agnes

Dirix, Luc Yves

Huizing, Manon Thirza

Jerusalem, Guy Heinrich Maria

Vuylsteke, Peter

De Cuypere, Eveline

Breiner, Doris

Mueller, Christian

Brignone, Chrystelle

Triebel, Frederic

机构：

[1] Clin Univ Saint Luc, King Albert II Canc Inst, Dept Med Oncol, Brussels, Belgium

[2] Catholic Univ Louvain, Inst Rech Experimentale & Clin Pole MIRO, Brussels, Belgium

[3] Erasmus MC Canc Inst, Rotterdam, Netherlands

[4] GZA St Augustinus, Oncol Cent GZA, TCRU, Antwerp, Belgium

[5] Univ Antwerp Hosp, Edegem, Belgium

[6] Univ Liege, Liege, Belgium

[7] CHU Sart Tilman Liege, Liege, Belgium

[8] Catholic Univ Louvain, CHU UCL Namur, Namur, Belgium

[9] Gen Hosp AZ Sint Jan Brugge Oostende, Brugge, Belgium

[10] Immutep, Clin Dev, Berlin, Germany

[11] Immutep, Res & Dev, Paris, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.1050

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1050

引用

页数：2

共 50 条

[1] Combination of paclitaxel and LAG3-Ig (IMP321), a novel MHC class II agonist as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Interim results from the run-in phase of a placebo controlled randomized phase II.
Duhoux, Francois P.
Jager, Agnes
Dirix, Luc
Huizing, Manon Thirza
Jerusalem, Guy Heinrich Maria
Vuylsteke, Peter
De Cuypere, Eveline
Breiner, Doris
Mueller, Christian
Brignone, Chrystelle
Triebel, Frederic
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[2] Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial
Wildiers, Hans
Armstrong, Anne
Cuypere, Eveline
Dalenc, Florence
Dirix, Luc
Chan, Steve
Marme, Frederik
Schroder, Carolina P.
Huober, Jens
Duhoux, Francois P.
Vuylsteke, Peter
Jager, Agnes
Brain, Etienne
Kuemmel, Sherko
Papai, Zsuzsanna
van Oordt, Catharina Willemien Menke-van der Houven
Perjesi, Luca
Mueller, Christian
Brignone, Chrystelle
Triebel, Frederic
CLINICAL CANCER RESEARCH, 2024, 30 (03) : 532 - 541
[3] FINAL RESULTS FROM AIPAC: A PHASE IIB COMPARING EFTILAGIMOD ALPHA (A SOLUBLE LAG-3 PROTEIN) VS. PLACEBO IN COMBINATION WITH WEEKLY PACLITAXEL IN HR+HER2-MBC
Wildiers, Hans
Dirix, Luc
Armstrong, Anne
De Cuypere, Eveline
Dalenc, Florence
Chan, Steven
Marme, Frederik
Schroder, Carolina Pia
Huober, Jens
Vuylsteke, Peter
Jacquin, Jean-Philippe
Brain, Etienne
Kummel, Sherko
Papai, Zsuzsanna
Mueller, Christian
Brignone, Chrystelle
Triebel, Frederic
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A997 - A997
[4] AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo controlled, multinational phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor positive metastatic breast cancer
Dirix, Luc
Wildiers, Hans
Huizing, Manon T.
De Cuypere, Eveline
Schroder, Carolina P.
Armstrong, Anne C.
Huober, Jans
Marme, Frederik
Schneeweiss, Andreas
Khan, Sarah
Triebel, Frederic
CANCER RESEARCH, 2020, 80 (04)
[5] AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo controlled, multinational phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor positive metastatic breast cancer.
Dirix, Luc
Jager, A.
Marme, Frederik
Brain, Etienne
Armstrong, Anne Caroline
Nawrocki, Sergiusz
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[6] Biomarker and multivariate analyses results from AIPAC: A phase IIb study comparing eftilagimod alpha (a soluble LAG-3 protein) vs placebo in combination with weekly paclitaxel in HR+HER2-metastatic breast cancer
Marme, F.
Wildiers, H.
Dirix, L.
Armstrong, A.
De Cuypere, E.
Dalenc, F.
Schroder, C. Pia
Vuylsteke, P.
Brain, E.
Kuemmel, S.
Papai, Z.
Mueller, C.
Brignone, C.
Triebel, F.
ANNALS OF ONCOLOGY, 2022, 33 : S203 - S204
[7] Primary efficacy results from AIPAC: A double-blinded, placebo controlled, randomized multinational phase IIb trial comparing weekly paclitaxel plus eftilagimod alpha (soluble LAG-3 protein) vs. weekly paclitaxel plus placebo in HR-positive metastatic breast cancer patients
Wildiers, Hans
Armstrong, Anne
Cuypere, Eveline
Dalenc, Florence
Dirix, Luc
Chan, Steve
Marme, Frederik
Schroder, Carolina Pia
Huober, Jens
Wagemans, Jill
Vuylsteke, Peter
Jacquin, Jean-Philippe
Brain, Etienne
Kummel, Sherko
Papai, Zsuzsanna
Perjesi, Luca
Mueller, Christian
Brignone, Chrystelle
Triebel, Frederic
CANCER RESEARCH, 2021, 81 (04)
[8] Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma.
Brana, Irene
Forster, Martin
Lopez-Pousa, Antonio
Doger, Bernard
Roxburgh, Patricia
Bajaj, Pawan
Portillo, Daniela Urueta
Quiroga, Vanesa
Krebs, Matthew
Mueller, Christian
Triebel, Frederic
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[9] TACTI-003: A RANDOMIZED PHASE IIB STUDY OF EFTILAGIMOD ALPHA (SOLUBLE LAG-3 PROTEIN) AND PEMBROLIZUMAB AS FIRST-LINE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Brana, Irene
Cheshuk, Valerii
Kristensen, Claus Andrup
Eugenia Ortega, Maria
Sautois, Brieuc
Lopez-Pousa, Antonio
Christian, Judith
Lybaert, Willem
Peguero, Julio
Park, John
Metcalf, Robert
Nabell, Lisle
Doger de Speville, Bernard
Rubio Casadevall, Jordi
Soria Rivas, Ainara
Forster, Martin
Triebel, Frederic
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A705 - A705
[10] A PHASE II STUDY OF EFTILAGIMOD ALPHA (SOLUBLE LAG-3 PROTEIN) AND PEMBROLIZUMAB IN PATIENTS UNSELECTED FOR PD-L1 EXPRESSION IN FIRST LINE METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Peguero, Julio
Triebel, Frederic
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A470 - A470

← 1 2 3 4 5 →